Would you like to provide feedback about your experience with ovarian cancer and the drug Olaparib/Lynparza?
Astra Zeneca Canada Inc., the pharmaceutical company that manufacturers this drug, will be applying to CADTH's* pan-Canadian Oncology Drug Review (pCODR) to seek a funding recommendation for the use of Olaparib (Lynparza) as maintenance treatment after first line platinum based chemotherapy for women who have tested positive for a BRCA genetic mutation.
The experiences of people who have been diagnosed with ovarian cancer and their caregivers are important considerations in the drug funding approval process. Ovarian Cancer Canada has prepared a survey to gather information from those individuals diagnosed with ovarian cancer and their caregivers so that your experiences can be included in the decision-making process.
Olaparib as a treatment is not a
Here are the links to the surveys for further information:
For women diagnosed with ovarian cancer:
For caregivers of women diagnosed with ovarian cancer:
This survey is open until April 7, 2019. Thank you for your participation. If you have any questions, please contact Marilyn Sapsford, Manager, National Programs. [email protected] or 1-877-413-7970 x231
*Canadian Agency for Drugs and Technology in Health